Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-04-08

Clinical Trial Update: Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis [Phase 3]

View source ↗

Summary

Phase 3 trial of tolebrutinib for generalized myasthenia gravis was terminated, but efficacy and safety results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tolebrutinib (tolebrutinib)

Snippet

Sponsor: Sanofi | Conditions: Myasthenia Gravis | Phase 3 | Status: TERMINATED | Results posted: 2024-04-08